Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T (2006) Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 19(1):95–110
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
COI: 1:CAS:528:DC%2BC3sXhsV2gu7vI, PID: 23835718
Morschhauser FA, Cartron G, Thieblemont C et al (2013) Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31(23):2912–2919
(2013)J Clin Oncol, vol.31, Issue.23, pp. 2912-2919
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study
COI: 1:CAS:528:DC%2BC3sXhsV2gu7vK, PID: 23835715
Salles GA, Morschhauser F, Solal-Céligny P et al (2013) Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31(23):2920–2926
(2013)J Clin Oncol, vol.31, Issue.23, pp. 2920-2926